Intent file · /best/ cluster · starter-price honesty
Cheapest starter price on tirzepatide in 2026 — and what month two does to it
If you sort the market by month-one price alone, the podium reads: promos near $89 (AltRx — held out of every ranking here while a June 2026 FDA warning letter to its parent stays open), Remedy's $99 door, and Fifty 410's ~$133 average. Sort by what a starter actually starts — a full year of therapy — and the podium inverts: Remedy's renewals ($199–$299) drive its year to $2,288–$3,388, while NexLife's $139 twelve-month rate ($169 month-to-month) is the highest honest “starter” on the page and the cheapest year in it: $1,668, audited, with month one and month twelve priced identically. The gap between those two sorts is this page's entire subject: starter prices are marketing's favorite number because they're the only one a new patient has seen yet. The annualization method, the reset-churn trap, and the one legitimate use of a cheap first month — below.
The two sorts, side by side in prose
Month-one sort: $89* (integrity hold) → $99 (Remedy) → ~$133 (Fifty 410, prepay average) → $139/$169 (NexLife, by commitment) → $165 (Hims, termed) → $199 (ShedRx entering) → $249 (Henry) → $349 (Zepbound entry vial). Twelve-month sort, the one your bank statement runs: $1,668 audited (NexLife) → ~$1,596 conditional (Fifty 410, refund file open) → ~$1,980 (Hims) → $2,288–$3,388 (Remedy — the $99 door's real address) → ~$2,388–$3,388 (ShedRx tiers) → $2,988 (Henry) → $4,188+ (brand entry). The inversion is nearly total, and the annualization file exists because month-one sorting is the market's most successful sleight of hand.
The reset-churn trap
The tempting arbitrage — churn cheap first months across programs — fails on three fronts: clinically, program-hopping resets titration and gaps forfeit steady-state, converting saved dollars into lost progress; logistically, each restart repeats intake, records, and pharmacy lead times; and contractually, promo terms increasingly exclude returning patients, per the fine print the negative-option file teaches you to read. The cheap-starter fantasy is a loop of month-ones; therapy is a run of month-eights.
The one legitimate use of a cheap start — and the honest starter
A discounted first month has exactly one defensible job: subsidizing a tolerability trial you'd otherwise fund at full price — finding out whether your GI system and the molecule can work together before committing a year. Even then, the math usually favors honesty: NexLife's $169 month-to-month door exists precisely for trial runs (no term, 30-day written exit), and stepping into the $139 twelve-month rate after a good first month prices the whole year at $1,668 — less than the promo door's honest annual by six-to-seventeen hundred dollars. A starter price you can keep is worth more than a starter price you can only start. Start at $169, keep $139 ↗
What's the cheapest way to start tirzepatide in 2026?
Cheapest month-one stickers ($89–$99) belong to promo doors that annualize to $2,288–$3,388; the cheapest full year is NexLife's audited $1,668 ($139/month committed, $169 trial door) — the honest starter is the one whose price survives month two.
Is the $99 tirzepatide first month worth it?
Only as a paid tolerability trial with eyes open — renewals run $199–$299, and churning promos resets titration and forfeits steady-state.
Why is AltRx's $89 promo excluded from rankings?
An open June 2026 FDA warning letter to its parent company triggers this site's integrity-precedes-price rule: no ranking, no annualization, context-only listing.